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ABSTRACT
Background: Treatment with anti-ulcer drugs has been shown to enhance IgE production against food anti-
gens. However, little is known about the immunological effects of cimetidine, a histamine receptor type 2 (H2R)
antagonist that is widely used as an anti-ulcer drug, in allergy. Therefore, the present study investigated the
role of cimetidine in Th2 immune responses in mice.
Methods: BALBc mice were immunized intraperitoneally with ovalbumin (OVA) with and without cimetidine.
The levels of cytokines in supernatants of spleen cells cultured in the presence of OVA for 4 days and the lev-
els of total and OVA-specific IgG1, IgG2a andor IgE in sera from these mice were determined by ELISA.
Results: Administration of cimetidine to OVA-sensitized BALBc mice promoted Th2 cytokine secretion by
OVA-stimulated spleen cells in vitro and increased serum levels of OVA-specific IgE, IgG1 and IgG2a.
Conclusions: These results indicate that cimetidine can enhance Th2 responses, suggesting that cimetidine
may contribute to IgE production in allergies.
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INTRODUCTION
Histamine receptor type 2 (H2R) antagonists such as
cimetidine are widely used as anti-ulcer drugs based
on their ability to accelerate healing of gastrointesti-
nal ulcers through inhibition of gastric acid secre-
tion.1-4 It is known that postoperative administration
of cimetidine to patients with gastrointestinal cancer
prolongs their survival5,6 by modulating immunologi-
cal responses, including inhibition of suppressor T
cell activation, promotion of NK cell function, and in-
duction of IL-2 and IL-12 production by T cells and pe-
ripheral blood mononuclear cells, respectively.7-10
Moreover, cimetidine can inhibit cellular proliferation
through blockade of histamine signal transduction in
vitro,11-13 while administration of cimetidine exacer-
bated delayed-type hypersensitivity in humans and
mice.14,15 On the other hand, Untersmayr et al. re-
cently reported that, similar to the case of proton
pump inhibitors, treatment with ranitidine, which is
another H2R antagonist and anti-ulcer drug, resulted
in preservation of pH-dependent antigenicity of food
antigens due to suppression of gastric acid secretion,
leading to enhanced IgE production against food anti-
gens.16-18 These observations suggest that cimetidine
may have similar effects to ranitidine on IgE produc-
tion, although the precise role of cimetidine in Th2
immune responses is poorly understood.
In the present study, therefore, we investigated the
effects of cimetidine on such Th2 immune responses
as Th2 cytokine and IgE production in mice sensi-
tized with an antigen, ovalbumin (OVA). We showed
that intraperitoneal administration of cimetidine to-
gether with OVA resulted in enhanced Th2 cytokine
secretion by spleen cells stimulated with OVA in vitro
and increased IgE levels in the sera.
METHODS
MICE
BALBc mice were obtained from Japan SLC, Inc.
(Shizuoka, Japan). Mice were maintained in a
pathogen-free facility and were used at 6 to 8 weeks
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Fig.　1　The scheme of cimetidine treatment. (A) BALB/c 
mice were sensitized intraperitoneally with 10 μg OVA in sa-
line on each of seven alternate days (days 0, 2, 4, 6, 8, 10 
and 12). Simultaneously, the mice were injected intraperito-
neally with 50 mg/kg cimetidine or saline, twice daily. Sera 
were collected on days 14 and 28, and each animal’s spleen 
was harvested on day 28. (B) On days 28, 31 and 34 after 
OVA with or without cimetidine, as in (A), the mice were 
challenged intranasally with 100 μg OVA or saline alone. 
One day after the last challenge, BALFs were collected.
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of age. All animal experiments were approved by the
animal care and use committee of Kyorin University
and the National Institute for Child Health and Devel-
opment.
INDUCTION OF ALLERGIC AIRWAY INFLAMMA-
TION
As shown in Figure 1, mice were immunized intrape-
ritoneally with 10 μg OVA (Sigma, MO, USA) in 100
μl of saline on each of seven alternate days (days 0, 2,
4, 6, 8, 10 and 12), as described elsewhere.19,20 Simul-
taneously, the mice were twice-daily injected intra-
peritoneally with the H2R antagonist, cimetidine
(TagametⓇ injection: Dainippon Sumitomo Pharma,
Osaka, Japan), or saline. Sera were collected on days
14 and 28, and the spleen of each mouse was har-
vested on day 28. On days 28, 31 and 34, the mice
were challenged intranasally with 100 μg OVA in 20
μl of saline or saline alone. One day after the last chal-
lenge, bronchoalveolar lavage fluids (BALFs) were
collected, and the cell types therein were identified as
described elsewhere.19-21
CELL CULTURE
Sixteen days after the last intraperitoneal immuniza-
tion with OVA (i.e., day 28), the spleen was collected
from the mice, and the single cell suspension of
spleen was prepared. After depletion of red blood
cells by treatment with a red blood cell lysing buffer
(Sigma), the spleen cells were suspended in RPMI
1640 medium supplemented with 10% fetal bovine se-
rum, 100 Uml of penicillin and 100 μgml of strepto-
mycin and cultured in the presence and absence of 25
μgml of OVA at 37℃ for 4 days in 24-well flat-
bottomed plates at a density of 4 × 106 cellsml. After
cultivation, the culture supernatants were collected
and stored at -30℃ until assay.
ELISA of IMMUNOGLOBULINS
The levels of OVA-specific mouse IgG1 and IgG2a in
sera were determined by ELISA. Briefly, the 96-well
plates were coated with 10 μgml of OVA in PBS at
4℃ overnight. For blocking, the wells were incubated
with 5% BSA in PBS at room temperature for 1 hour.
Diluted mouse sera were dispensed into the wells
and incubated at room temperature for 2 hours. For
detection of OVA-specific IgG1 and IgG2a, the wells
were incubated with HRP-conjugated anti-mouse
IgG1 and IgG2a (Jackson Laboratory, ME, USA), re-
spectively. After washing the wells, enzymatic reac-
tion was performed by adding a TMB substrate (BD
Biosciences, CA, USA) to each well. The reaction was
stopped by addition of 2N H2SO4. Pooled mouse
high-titer anti-OVA serum was used as a standard for
these ELISAs. The levels of OVA-specific and total
mouse IgE in sera were determined with a DS Mouse
IgE ELISA (OVA) kit (DS Pharma Biomedical,
Osaka, Japan) and a mouse IgE ELISA Quantitation
Kit (Bethyl Laboratories, Inc., TX), respectively.
ELISA FOR CYTOKINES
For the detection of cytokines in the culture superna-
tants of spleen cells, mouse IL-4 and IFN-γ OptEIATM
ELISA Kit (BD Biosciences), DuoSetⓇ mouse IL-13
ELISA kit (R&D Systems, MN, USA), and mouse IL-5
and IL-17 ELISA kits (eBioscience, CA, USA) were
used.
STATISTICAL ANALYSIS
The results were expressed as the mean + SE. The
significance of differences between means was deter-
mined by Student’s 2-tailed t-test, and differences
were considered statistically significant when p <
0.05.
RESULTS
EFFECT OF CIMETIDINE ON IMMUNOGLOBULIN
PRODUCTION
We first examined the effect of cimetidine on circulat-
ing OVA-specific IgE production in mice that had
been sensitized intraperitoneally with OVA in the
presence or absence of cimetidine (Fig. 1A). The se-
rum levels of OVA-specific IgE were determined by
ELISA on days 14 and 28 after the first immunization
with OVA ± cimetidine. The serum levels of OVA-
specific IgE in mice immunized with OVA alone were
significantly increased in comparison with those in
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Fig.　2　The effects of cimetidine on immunoglobulin produc-
tion in OVA-sensitization mice. Mice were immunized with 
OVA, with or without cimetidine, as in Figure 1A. (A) On days
14 and 28 after the fi rst immunization, the levels of OVA-spe-
cifi c IgE in sera were determined by ELISA. (B) On day 28 
after the fi rst immunization, the levels of total IgE, OVA-spe-
cifi c IgG1 and OVA-specifi c IgG2a were measured by ELISA.
Data show the mean + SE (n = 8-13 mice). *p < 0.05 versus 
naïve mice, and **p < 0.05 versus mice treated with OVA 
alone. Cim = cimetidine.
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naïve mice (Fig. 2A). Interestingly, administration of
cimetidine at 50 mgkg, but not 10 mgkg, to mice
during OVA sensitization resulted in a 2- to 4-fold in-
crease in the serum level of OVA-specific IgE (Fig. 2
A and data not shown). Unlike OVA-specific IgE, the
serum levels of total IgE on day 28 after the first OVA
immunization were not influenced by administration
of 50 mgkg cimetidine (Fig. 2B). We also found that
on day 28 after the first immunization the levels of
OVA-specific IgG1 and IgG2a in sera from mice
treated with OVA plus 50 mgkg cimetidine were sig-
nificantly increased compared with those from mice
treated with OVA alone (Fig. 2B). These observations
clearly indicated that the intraperitoneal administra-
tion of cimetidine to mice enhanced antigen-specific
IgE and IgG production. In contrast to i.p. treatment,
intraoral administration with cimetidine did not en-
hance total and antigen-specific immunoglobulin pro-
duction at a dosage of 50-200 mgkg (data not
shown).
EFFECT OF CIMETIDINE ON Th2 CYTOKINE
PRODUCTION
We next investigated the effect of cimetidine on Th2
cytokine production by spleen cells in vitro. Spleen
cells, obtained from mice on day 28 after the first im-
munization with OVA in the presence or absence of
50 mgkg cimetidine, were cultured in the presence
of 25 μgml of OVA for 4 days. The levels of cytoki-
nes in the culture supernatants were determined by
ELISA. The levels of IL-5, a Th2-type cytokine in the
culture supernatants of spleen cells from mice treated
with OVA plus cimetidine were significantly in-
creased in comparison with those from mice treated
with OVA alone (Fig. 3). IL-4, which is a major Th2-
type cytokine, was below the limit of detection of the
ELISA (data not shown). In contrast to IL-5, the levels
of IL-13, another Th2-type cytokine, IFN-γ, a Th1-type
cytokine, and IL-17, a Th17-type cytokine, did not dif-
fer as a function of the treatment (Fig. 3). These ob-
servations suggest that cimetidine plays an important
role in the activation of Th2, but not Th1 or Th17,
cells in the sensitization phase to allergens in vivo.
EFFECT OF CIMETIDINE ON INDUCTION OF AL-
LERGIC AIRWAY INFLAMMATION
Based on the above observations, we next investi-
gated the effects of cimetidine on the elicitation phase
of Th2 cellcytokine-mediated allergic airway inflam-
mation. Mice were immunized intraperitoneally with
OVA, with or without 50 mgkg cimetidine, and then
challenged intranasally with OVA or saline alone
(Fig. 1B). One day after the last challenge, BALFs
were collected, and the cell types therein were deter-
mined. The numbers of eosinophils as well as neutro-
phils, lymphocytes and macrophages in the BALFs
from OVA-challenged mice were significantly in-
creased in comparison with those from saline-treated
mice (Fig. 4A). In accordance with this, the levels of
IL-4 and IL-5, but not IL-13, in the BALFs from the
OVA-challenged mice were also markedly increased
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Fig.　3　The effect of cimetidine treatment on Th2 cytokine production by spleen 
cells. Mice were immunized with OVA, with or without cimetidine, as in Figure 1A. 
On day 28 after the fi rst immunization, each animal’s spleen was collected, and the 
single cell suspension of spleen was prepared. Spleen cells were cultured in the 
presence or absence of 25 μg/ml of OVA for 4 days. The levels of cytokines in the 
culture supernatants were measured by ELISA. Data show the mean + SE (n = 
8-13 mice). *p < 0.05 versus mice treated with OVA alone. Cim = cimetidine.
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compared with those from the saline-treated mice
(Fig. 4B). In contrast to Th2 cytokines, the level of
IFN-γ in BALFs was decreased in mice challenged
with OVA comparing to mice treated with saline.
However, administration of cimetidine during sensiti-
zation with OVA did not influence the numbers of
such cells or the levels of IL-4, IL-5 and IL-13 in
BALFs after the OVA and saline inhalation (Fig. 4A,
B). These observations suggest that treatment of ci-
metidine during sensitization with antigens did not in-
fluence the induction of Th2-type cytokine-mediated
immune responses such as eosinophilia in the elicita-
tion phase following antigen challenge.
DISCUSSION
Cimetidine, an H2R antagonist that is widely used as
an antiulcer drug, modulates various immune re-
sponses. However, little has been known about the
immunological effects of cimetidine on Th2-type im-
mune responses, leading us to investigate its effects
on OVA-mediated Th2-type immune responses in
BALBc mice. It was reported that inhibition of inter-
action of histamine and H2R by addition of H2R an-
tagonists such as ranitidine accelerated Th2 cell pro-
liferation,22 suggesting that ranitidine has the ability
to enhance Th2 immune responses. Consistent with
this, we found that production of antigen-specific se-
rum IgE and IgG1 and IL-5, a Th2-type cytokine, by
antigen-stimulated spleen cells was significantly en-
hanced by intraperitoneal administration of ci-
metidine during the sensitization phase of OVA-
induced airway inflammation.
Based on the effects of cimetidine in IgE and Th2-
type cytokine production during the sensitization
phase of antigens, it was expected that cimetidine
would be involved in the induction of OVA-induced
Th2-type cellcytokine-mediated airway inflamma-
tion. In contrast, neither the eosinophil count nor the
IL-4 and IL-5 levels in BALFs was influenced by the
prior treatment with cimetidine in the elicitation
phase of OVA-induced airway inflammation.
We found that in addition to the production of Th2-
type cytokine-dependent Igs such as IgE and IgG1,
production of antigen-specific IgG2a, which is consid-
ered to be mediated by Th1-type cytokines,23,24 was
also augmented by the intraperitoneal treatment with
cimetidine in the sensitization phase of OVA-induced
airway inflammation. This observation suggests that
cimetidine is able to modulate Th1-type immune re-
sponses as well as Th2-type immune responses in
Cimetidine Enhances IgE Production
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Fig.　4　The effect of cimetidine treatment on airway infl ammation. Mice were im-
munized with OVA, with or without cimetidine, and challenged with OVA or saline 
alone, as in Figure 1B. One day after the last challenge, BALFs were collected. (A) 
The number of cells and (B) the levels of cytokines in the BALFs were determined. 
Data show the mean + SE (n = 8-13 mice). Cim = cimetidine.
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spite of the fact that cimetidine was not involved in in-
duction of antigen-induced Th1 cells in the spleen of
mice after the sensitization with OVA. In support of
this, it has been reported that cimetidine enhanced
production of Th1 cytokines,10,25,26 Th1-type cytokine-
mediated immune responses such as anti-tumor activ-
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ity and delayed-type hypersensitivity in humans and
mice.5,6,14,15
In contrast to the sensitization phase, cimetidine
did not contribute to induction of Th2-type cytokine-
mediated immune responses such as eosinophilia in
the elicitation phase following antigen challenge. This
might be explained by the fact that cimetidine could
enhance not only Th2 responses, but also Th1 re-
sponses. It seemed that the enhanced Th2 responses
by cimetidine may be reciprocally suppressed by the
increased Th1 responses by cimetidine in the local in-
flammatory sites.
In conclusion, cimetidine treatment significantly
enhanced antigen-specific IgE and Th2-type cytokine
production in OVA-sensitized mice. These results in-
dicate that cimetidine may contribute to IgE produc-
tion in allergic disorders.
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